OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Northeast GI Oncology Congress 2026: Two Days of Science, Debate, and New Perspectives in GI Cancer Care

Taofeek K. Owonikoko Named Candidate for ASCO President-Elect

Merck's Sacituzumab Tirumotecan Improves Survival in Advanced Gastroesophageal Cancer in Phase 3 TroFuse Trial

Pelotonia Raises Record $31.1 Million in 2026, Bringing Total Cancer Research Funding Beyond $370 Million

ECO Calls on EU Governments to Protect Cancer Care During Crises

Verismo Therapeutics Licenses Stanford Technology for In Vivo CAR T Therapy

Pumitamig Plus Nab-Paclitaxel Achieves 73.8% Response Rate in First-Line Advanced Triple-Negative Breast Cancer

Immune Oncology

OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.